Studies related to Liver Cirrhosis and L-Carnitine

L-Carnitine For The Treatment Of Overt Hepatic Encephalopathy In Patients With Advanced Liver Cirrhosis

Effect Decrease
Values Figure 2
Trial Design Non-randomized controlled trial
Trial Length 1-7 Days
Number of Subjects 45
Sex Both Genders
Notes for this study:
In a retrospective, observational study, 45 participants with overt hepatic encephalopathy and advanced liver cirrhosis were analyzed, as they had taken 1,000 mg of l-carnitine along with normal treatment (including BCAAs), or only received normal treatment with BCAAs. Some patients took 1,500 mg-2,000 mg of l-carnitine daily after being discharged.

Blood ammonia was lower after 7 days when taking carnitine. Liver function also improved in the l-carnitine group, and recurrence-free survival was greater in the follow-up.